Brief: Akero Therapeutics Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025
07/11/2025 12:32
Nov 7 (Reuters) - Akero Therapeutics Inc AKRO.O: AKERO THERAPEUTICS PRESENTS NEW ANALYSES FROM PHASE 2B SYMMETRY AND HARMONY TRIALS OF EFRUXIFERMIN AT 76TH ANNUAL AASLD THE LIVER MEETING® 2025 Source text: ID:nGNX2WgJ15 Further company coverage: AKRO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akero Therapeutics
See all newsBrief: Novo Nordisk Completes Acquisition Of Akero Therapeutics
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Germany's Cartel Office Says It Approved Acquisition Of Akero Therapeutics By Novo Nordisk
Brief: Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk